Not yet recruiting
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
NCT07747493· University Health Network, Toronto· Source
Contact: Adriano Basso Dias, MD, Radiologist
Recruiting
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
NCT06634056· Phase 2· University Health Network, Toronto· Source
Contact: Philip Wong MD
Recruiting
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
NCT07628751· University Health Network, Toronto· Source
Contact: Michael Yan, MD MPH FRCPC DABR
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Contact: Communication Center
Recruiting
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
NCT06654336· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source
Contact: Dr Aruz Mesci, MD
Recruiting
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
NCT07456605· Phase 1· University Health Network, Toronto· Source
Contact: Guido Lancman, M.D.
Recruiting
Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study
NCT07376837· University Health Network, Toronto· Source
Contact: Sangeet Ghai, MD
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559· Phase 2· ALX Oncology Inc.· Source
Contact: Cheng Quah, MD
Recruiting
Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
NCT07339943· University Health Network, Toronto· Source
Contact: Kateri Corr
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126· Phase 3· Immatics US, Inc.· Source
Contact: Marcus Butler, MD
Recruiting
Comparing Moderately and Ultra Hypofractionated Radiation Treatments for Post-operative Prostate Cancer
NCT06409910· Phase 2· University Health Network, Toronto· Source
Contact: Andrew McPartlin
Recruiting
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
NCT06345079· Phase 2· Australasian Gastro-Intestinal Trials Group· Source
Contact: Dr Raymond Jang
Active, not recruiting
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
NCT06377111· Phase 1· University Health Network, Toronto· Source
Active, not recruiting
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733· Phase 3· Ivy Brain Tumor Center· Source
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· Phase 2/3· Daiichi Sankyo· Source
Active, not recruiting
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740· Phase 1· TORL Biotherapeutics, LLC· Source
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826· Phase 1· TORL Biotherapeutics, LLC· Source
Recruiting
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer
NCT05582772· University Health Network, Toronto· Source
Contact: Shabbir Alibhai, MD
Active, not recruiting
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030· Phase 1· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
NCT05327647· Phase 2· CHU de Quebec-Universite Laval· Source
Contact: Girish Kulkarni, BSc, MD, PhD, FRCSC
Recruiting
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616· Phase 3· University College, London· Source
Contact: Marie Kirchmeyer
Active, not recruiting
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622· Phase 3· Pfizer· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Contact: enGene clinical trials
Recruiting
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT04575935· Phase 3· M.D. Anderson Cancer Center· Source
Contact: Liat Hogen, MD
Active, not recruiting
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362· Phase 1/2· BicycleTx Limited· Source
Active, not recruiting
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317· Phase 3· Pfizer· Source
Recruiting
SABR for Renal Tumors
NCT03747133· University Health Network, Toronto· Source
Contact: Andrew McPartlin, MD
Active, not recruiting
Palliative Thoracic ImmunoRT
NCT03705806· University Health Network, Toronto· Source
Recruiting
MR Guidance for Liver and Pancreas
NCT03582189· University Health Network, Toronto· Source
Contact: Laura Dawson, MD
Active, not recruiting
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
NCT03030261· Phase 2· Washington University School of Medicine· Source
Active, not recruiting
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT03127631· McMaster University· Source
Active, not recruiting
Economic Analysis of Alliance A041202 CLL Study
NCT02414022· Canadian Cancer Trials Group· Source
Active, not recruiting
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· Phase 3· Pfizer· Source
Active, not recruiting
18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer
NCT02701699· University Health Network, Toronto· Source